WeedMarketCap
Legal MapCommunity
WeedMarketCap

Cannabis market data, tracked daily.

Where Is Weed Legal? Map 2026CommunityAboutContactPrivacy Policy

Prices may be delayed. This site is for informational purposes only and does not constitute financial advice. Cannabis stocks carry significant risk — always do your own research.

© 2026 WeedMarketCap. All rights reserved.

WeedMarketCap
Legal MapCommunity
Back to market table
CRON logo

Rank #7

Cronos Group Inc. (CRON) Stock Price

Nasdaq · Cannabis stock on WeedMarketCap

$3.25

+1.25% (24h)

Last updated: 1 second ago

Market Cap

$1.2B

Volume (24h)

781.85K

Last Close (7D)

$3.25

View on TradingView
Earnings Nov 5 · in 17d

Latest Quarter

Q1 FY2026ended 2026-03-31 · filed 2026-05-11

View 10-Q on SEC
Revenue

$45.21M

+40.13% YoY
Net Income

$13.75M

+124.63% YoY
Operating Income

$-1.83M

+54.99% YoY
EPS (Diluted)

$0.04

+100.00% YoY
Cash

$821.86M

Total Assets

$1.17B

Equity

$1.07B

Long-term Debt

N/A

What this quarter tells us

Cronos Group reported strong revenue growth and a swing to net profitability in Q1 FY2026, driven by a 40% YoY revenue increase and improved operating leverage. The balance sheet remains fortress-like with $822M cash and zero debt, and no dilution events in the past 12 months.

  • •Revenue rose 40.1% YoY to $45.2M, accelerating from prior-year growth; net income more than doubled to $13.8M ($0.04 EPS) from $6.1M, though the prior-year period was a weak base.
  • •Operating loss narrowed 55% to -$1.8M, indicating improving cost efficiency; the company is approaching operating breakeven.
  • •Balance sheet is extremely strong: $821.9M cash, $1.07B equity, and zero long-term debt; no capital raises or dilution events in the last 12 months.

Informational summary based on SEC XBRL figures · generated by AI agent. Not investment advice.

Earnings reports (12m): 4Dilution / offering filings (12m): 0Source: SEC EDGAR XBRL

Company Profile

Exchange
Nasdaq
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
610
Website
thecronosgroup.com
Country
🇨🇦 Canada

A Canadian LP majority-backed by Altria (parent of Marlboro), Cronos is a capital-light brand play targeting premium cannabis wellness and lifestyle consumers worldwide.

  • 🚬 Altria's 45%+ stake gives Cronos the financial muscle and distribution know-how of a tobacco giant
  • ✨ Lord Jones and Spinbrands position the company in premium CBD and lifestyle cannabis segments
  • 💊 Biosynthesis research into rare cannabinoids represents a long-term technology differentiation bet

Key Stats

52-Week Range
$2.28$3.61
Beta1.20
Trailing P/E17.11
Forward P/E-81.25
Trailing EPS0.19
Avg Volume

Earnings & Analyst

Next Earnings2026-11-05
EPS EstimateN/A
Target Mean Price$2.49
RecommendationStrong Buy
Recommendation Mean1.40

Recent SEC Filings

All filings
  • Shareholder vote

    Submission of Matters to a Vote of Security Holders. Cronos Group Inc. (the company ) held its 2026 Annual Meeting of Shareholders on June 18, 2026 (the Meeting ).

    8-K · 5.07

    2026-06-22

    SEC

  • Quarterly report

    Filed quarterly report for period ended 2026-03-31 (10-Q).

    10-Q

    2026-05-11

    SEC

  • Earnings results

    Entry into a Material Definitive Agreement. On May 8, 2026, Cronos Group Inc. (the company ), its indirect wholly owned subsidiary, CGM B.V.

Frequently Asked Questions

What does Cronos Group (CRON) do?

Cronos Group is a Canadian licensed cannabis producer (LP) that focuses on building premium cannabis wellness and lifestyle brands for consumers worldwide. The company is known for its capital-light brand strategy, emphasizing product development and marketing over large-scale cultivation. Key brands include Lord Jones, a premium CBD line, and Spinbrands, which targets the lifestyle cannabis segment. Cronos also invests in biosynthesis research to produce rare cannabinoids, positioning itself for long-term differentiation in the market.

What is Cronos Group's business model?

Cronos Group operates a capital-light business model, meaning it prioritizes brand development and partnerships over owning extensive cultivation facilities. This approach allows the company to leverage its strong balance sheet and the expertise of its majority stakeholder, Altria (the parent company of Marlboro), which holds over a 45% stake. By focusing on premium brands like Lord Jones and Spinbrands, Cronos aims to capture higher margins in the cannabis wellness and lifestyle segments. Additionally, the company invests in biosynthesis research to create rare cannabinoids, which could provide a technological edge in the future.

Which markets does Cronos Group serve?

Cronos Group serves consumers worldwide, with a particular emphasis on premium cannabis wellness and lifestyle products. While the company is headquartered in Canada and operates as a Canadian LP, its brands like Lord Jones and Spinbrands are designed for global distribution. The company's partnership with Altria provides access to extensive distribution networks and market insights, potentially facilitating expansion into international markets. However, specific country-level market details are not provided in the available data.

What is Cronos Group's role in the cannabis sector?

Cronos Group is categorized as a Canadian licensed cannabis producer (LP), which means it is authorized to cultivate, process, and sell cannabis in Canada under federal regulations. Unlike many LPs that focus on large-scale cultivation, Cronos differentiates itself through a brand-centric, capital-light strategy. The company targets the premium segment of the market, emphasizing wellness and lifestyle products. Its significant backing from Altria, a major tobacco company, sets it apart from other LPs and provides financial stability and strategic distribution expertise.

What are Cronos Group's notable brands or differentiators?

Cronos Group's notable brands include Lord Jones, a premium CBD brand, and Spinbrands, which focuses on lifestyle cannabis products. These brands position the company in the high-end wellness and lifestyle segments. A key differentiator is Altria's majority stake of over 45%, which gives Cronos access to the financial resources and distribution know-how of a global tobacco giant. Additionally, Cronos is investing in biosynthesis research to produce rare cannabinoids, representing a long-term technology bet that could set it apart from competitors in the future.

Latest News

  • Yahoo · 15h ago

    3 Canadian Penny Stocks With Market Caps Over $1 Billion

  • Yahoo · 23h ago

    ACT Energy Technologies And 2 Canadian Penny Stocks To Watch

  • Yahoo · Oct 17, 2026

    Top 3 Canadian Healthcare Stocks To Watch In October 2026

  • Yahoo · Oct 17, 2026

    3 Canadian Penny Stocks To Own In October 2026

  • Yahoo · Oct 15, 2026

    Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company

  • Yahoo · Oct 15, 2026

    3 Canadian Biotech Stocks Trading Up To 93% Below Fair Value

1.14M
Enterprise Value$450.39M
Shares Outstanding368.41M

8-K · 1.01,2.02,8.01,9.01

2026-05-11

SEC

  • Proxy statement

    Proxy statement filed on 2026-04-24 (DEF 14A).

    DEF 14A

    2026-04-24

    SEC

  • Annual report

    Filed annual report for year ended 2025-12-31 (10-K).

    10-K

    2026-02-26

    SEC

  • Earnings results

    Results of Operations and Financial Condition. On February 26, 2026 , Cronos Group Inc. (the company ) issued a press release announcing its financial results for its fourth quarter and full year ended December 31, 2025.

    8-K · 2.02,9.01

    2026-02-26

    SEC

  • Material agreement

    Entry into a Material Definitive Agreement. On December 9, 2025 , Cronos Group Inc. (the company ), and its wholly owned subsidiary, CGM B.V.

    8-K · 1.01,7.01,9.01

    2025-12-09

    SEC

  • Quarterly report

    Filed quarterly report for period ended 2025-09-30 (10-Q).

    10-Q

    2025-11-06

    SEC

  • Earnings results

    Results of Operations and Financial Condition. On November 6, 2025 , Cronos Group Inc. (the company ) issued a press release announcing its financial results for its third quarter ended September 30, 2025.

    8-K · 2.02,9.01

    2025-11-06

    SEC

  • Officer / director change

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    8-K · 5.02

    2025-08-29

    SEC